Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7053769 | 0.80 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL9752077 | 0.78 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL11519020 | 0.75 | PRKCA (0.31) | — | |
| SCHEMBL3860628 | 0.72 | ALDH1A1 (0.30) | — | |
| SCHEMBL2710911 | 0.69 | PTPN1 (0.40) | — | |
| SCHEMBL6200554 | 0.68 | — | — | |
| Butane SCHEMBL379581 | 0.67 | PTPN1 (0.40) | — | |
| SCHEMBL8053864 | 0.67 | PTPN1 (0.42) | — | |
| SCHEMBL8775757 | 0.65 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL4938476 | 0.65 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475607-B | Method for preparing capsules containing at least one water-soluble or hydrophilic substance and capsules obtained by said method | 卡莉西亚公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-2220047-B1 | Quinoline derivatives, pharmaceutical compositions comprising them, and use thereof | CLANOTECH AB (SE) | 2015-05-06 | — | — | EP | disclosed |
| US-8957092-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2015-02-17 | — | — | US | disclosed |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANO TECH AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8557843-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | CLANOTECH AB (SE) | 2013-10-15 | — | — | US | disclosed |
| EP-2432764-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | ClanoTech AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2220047-A2 | COMPOUNDS AND METHODS | ClanoTech AB (SE) | 2010-08-25 | — | — | EP | disclosed |
| EP-1687276-B1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009063070-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | CLANOTECH AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| EP-1117647-A1 | METHOD FOR PREPARING 4-HYDROXYQUINOLINES AND/OR TAUTOMERIC FORMS | RHODIA CHIMIE (FR) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018739-A1 | METHOD FOR PREPARING 4-HYDROXYQUINOLINES AND/OR TAUTOMERIC FORMS | RHODIA CHIMIE (FR) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053976-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BRAF, MAP3K1, MAP3K7 | SMN1; SMN2 2393/4885 |
| US-20140018388-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | BRAF, TYK2, MAP3K6 | SMN1; SMN2 3369/4885 |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | FLT1, FLT4, VEGFA | SMN1; SMN2 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.